Recombinant proteins used in biomedical research, diagnostics and different therapies are
mostly produced in Chinese hamster ovary cells in the pharmaceutical industry. These …

Large scale biopharmaceutical production of biologics relies on the overexpression of
foreign proteins by cells cultivated in stirred tank bioreactors. It is well recognized and …

Although most therapeutic monoclonal antibodies (mAbs) can routinely be produced in the
multigram per litre range, some mAb candidates turn out to be difficult‐to‐express (DTE). In …

Chinese hamster ovary (CHO) cells present inherent limitations for processing and secretion
of large amounts of recombinant proteins, especially for those requiring complex post …

With the advent of novel therapeutic proteins with complex structures, cellular bottlenecks in
secretory pathways have hampered the high-yield production of difficult-to-express (DTE) …

Chinese hamster ovary (CHO) cells are utilized as primary mammalian expression host cells
for the production of biopharmaceuticals. Recombinant CHO cell line development (CLD) …

Bispecific protein scaffolds can be more complex than traditional monoclonal antibodies
(MAbs) because two different sites/domains for epitope binding are needed. Because of this …

Low culture temperature enhances the cell‐specific productivity of Chinese hamster ovary
(CHO) cells expressing varied recombinant (r‐) proteins, but the mechanisms remain …

Mammalian cell factories (in particular the CHO cell system) have been crucial in the rise of
biopharmaceuticals. Mammalian cells have compartmentalized organelles where intricate …

Most of the recombinant biotherapeutics employed today to combat severe illnesses, for
example, various types of cancer or autoimmune diseases, are produced by Chinese …